ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Transplantation · Clin Transplant · 2026-10-01

Secondary analysis of two RCTs in heart transplant recipients (SCHEDULE, n=83; NOCTET, n=75): replacing calcineurin inhibitors with everolimus, or reducing calcineurin inhibitor dose with everolimus, did not change left ventricular mass versus standard calcineurin inhibitors.

Secondary analysisn = 158
Murbraech et al. Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients-Results From Two Randomized Controlled Trials
Transplantation · Transpl Int · 2026-09-23

In an open-label RCT of 60 kidney transplant recipients (of 100 planned) with late active AMR and de novo DSA, adding bortezomib to standard care did not improve the 12-month composite endpoint (40.0% vs 33.3%; p=0.59) and raised serious adverse events (76.7% vs 46.7%).

RCTn = 60
Snanoudj et al. Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial
Transplantation · Am J Transplant · 2026-08-22

Updated American Society of Transplantation guidelines on vaccination, travel and safe living for solid organ transplant candidates and recipients, adding COVID-19 and RSV vaccines and noting live-attenuated vaccines can be given to select young recipients.

Guideline
Kumar et al. Vaccination and safe living strategies for solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Transplantation · Bone Marrow Transplant · 2026-08-21

In a randomised pilot trial of 79 patients with AML or MDS having 8/8 HLA-matched donor transplants, ATG plus post-transplant cyclophosphamide gave similar 100-day survival to ATG alone (94.9% vs 95.0%, p>0.9); median neutrophil engraftment was slower (22 vs 19 days).

RCTn = 79
Walker et al. A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium
Transplantation · J Heart Lung Transplant · 2026-06-11

ISHLT scientific statement from a multidisciplinary expert workgroup (modified Delphi, 9 subgroups) updating the 2016 definition of lung antibody-mediated rejection, proposing the GAP definition: Graft dysfunction, Antibodies and Pathological findings.

Guideline
Calabrese et al. International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition
Transplantation · Am J Transplant · 2026-05-22

In 31 adult transplant recipients (30 solid organ) with norovirus, nitazoxanide did not shorten median time to symptom resolution vs placebo (19.0 vs 11.0 days; P=.459) or time to negative stool PCR; no serious drug-related adverse events.

RCTn = 31
Boutin et al. A phase 2 multicenter, prospective, randomized, double-blind study to assess the clinical and antiviral efficacy and safety of nitazoxanide for the treatment of norovirus in hematopoietic stem cell and solid organ transplant recipients
Transplantation · Transplantation · 2026-05-04

Phase 1 dose-escalation RCT in 60 healthy participants: single subcutaneous or intravenous doses of VEL-101 (anti-CD28) vs placebo were generally well tolerated, mostly mild-moderate adverse events; one serious event (grade 3 rhabdomyolysis) resolved.

RCTn = 60
Tremblay et al. Safety, Pharmacokinetics, and Pharmacodynamics of Fixed-dose, Subcutaneous, and Intravenous Administration of VEL-101, an Anti-CD28 PEGylated Monoclonal Antibody Fragment, in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase 1 Study
Transplantation · Transplant Cell Ther · 2026-04-30

In a phase II trial of 128 adults with AML or ALL having unrelated or haploidentical transplant, PTCy-ruxolitinib was non-inferior to PTCy-tacrolimus-MMF for grade II-IV acute GVHD at 125 days (12.9% vs 21.2%), with less kidney injury; survival did not differ.

RCTn = 128
Moiseev et al. A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide
Transplantation · Am J Transplant · 2025-11-26

In a randomised trial of 15 kidney transplant recipients with subclinical graft inflammation, polyclonal Treg infusion did not change graft inflammation at 6 months significantly vs control; inflammation fell in both groups. No adverse events were seen with Tregs.

RCTn = 15
Chandran et al. Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.